Drug Profile
Research programme: anti-protozoan therapeutics - Astellas Pharma/Nagasaki University
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Developer Astellas Pharma; Nagasaki University School of Medicine
- Class Antiprotozoals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported African trypanosomiasis; Chagas disease; Leishmaniasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in African trypanosomiasis in Japan
- 16 Jul 2016 No recent reports of development identified for research development in Chagas'-disease in Japan
- 16 Jul 2016 No recent reports of development identified for research development in Leishmaniasis in Japan